Palette Life Sciences, a fully integrated life sciences company, today announced it has partnered with EVERSANA™, a leading provider of commercial services to the life science industry, to enhance market access, commercialization, and distribution activities of Solesta™ in the United States.
|
SANTA BARBARA, Calif. and STOCKHOLM, Sept. 28, 2020 /PRNewswire/ -- Palette Life Sciences, a fully integrated life sciences company, today announced it has partnered with EVERSANA™, a leading provider of commercial services to the life science industry, to enhance market access, commercialization, and distribution activities of Solesta™ in the United States.
Solesta is the only FDA-approved minimally invasive treatment for bowel incontinence. It is an injectable, viscous gel made from two polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA®) and unique Dextranomer (Dx) microspheres. Fecal or bowel incontinence affects millions of people worldwide. The American Society of Colon and Rectal Surgeons (ASCRS) clinical practice guidelines for fecal incontinence states that up to 18% of the general population worldwide suffer from the disorder. Due to the emotional toll and perception of ineffective treatments, many patients with the condition avoid seeking treatment, and actual prevalence is likely higher. "We have a remarkable opportunity to make a positive impact on the lives of millions of people worldwide. Solesta is an effective therapy that deserves the right commercial strategy to improve awareness among caregivers, enhance market access for patients, and provide important physician support services. These initiatives allow us the opportunity to drive a positive long term quality of life impact for those who are suffering every day. We are certain that EVERSANA has the right capabilities and team to meet the needs of our stakeholders," said James Leech, Head of Strategy & Corporate Development, Palette Life Sciences. Palette will utilize EVERSANA's commercial execution expertise to optimize market access, HCP engagement, distribution, patient services and hub support, as well as nationwide distribution of Solesta. Palette and EVERSANA have employed a novel approach to help address financial challenges facing HCP offices amidst what can be a complex payment environment. The enhanced program will allow HCPs to work directly with EVERSANA on billing and reimbursement needs. "We are eager to begin utilization of this important new resource and feel that it can have a meaningful impact on solving existing barriers to Solesta market access. Palette's investment into Solesta, including product improvements, training solutions, generation of important new clinical data, and a commitment to improving the lives of patients via enhanced support and market access is commendable," said Colorectal Surgeon & Specialist Zuri A. Murrell, M.D., Director, Colorectal Cancer Program, Clinical Chief of Colorectal Surgery & Attending Surgeon at Cedars-Sinai Medical Center. Jim Lang, CEO of EVERSANA, added, "This is exactly why EVERSANA exists. There are amazing therapies approved by the FDA but not meeting their optimal commercial success. With Palette leadership we will take a complete look across the product life cycle to add greater effectiveness and outcomes. It is what their patients deserve." Terms of the agreement will not be disclosed. About Solesta About Palette Life Sciences About EVERSANA™ Palette Contacts: EVERSANA Contact: +1 (414) 434-4691
SOURCE EVERSANA |
View original content to download multimedia:
